Kite, a Gilead Company
Clinical trials sponsored by Kite, a Gilead Company, explained in plain language.
A cell therapy company focused on CAR-T treatments for cancer, owned by Gilead Sciences.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- One-Time infusion aims to build cancer killers inside the body Results expected Oct 2026 (estimated)
- New immune cell therapy takes on tough lymphoma Results expected Nov 2026 (estimated)
- Engineered immune cells take on Hard-to-Treat myeloma Results expected Dec 2026 (estimated)
- CAR T-Cell therapy takes on tough blood cancers in japanese trial Results expected Jul 2027 (estimated)
-
New CAR T-Cell therapy aims to outperform current treatment for aggressive lymphoma
Disease control Recruiting nowThis phase 3 trial tests whether a new CAR T-cell therapy, KITE-753, works better than the current standard, axicabtagene ciloleucel (axi-cel), for adults with large B-cell lymphoma that returned or didn't respond to first treatment. About 550 participants will receive one infusi…
Phase 3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New Dual-Targeting CAR T-Cells aim to outsmart tough lymphoma
Disease control Recruiting nowThis study is testing two experimental treatments, KITE-363 and KITE-753, for people with B-cell lymphoma that has returned or stopped responding to standard therapy. These are personalized cell therapies made from a patient's own immune cells, engineered to attack two targets (C…
Phase 1/2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Engineered immune cells take on multiple sclerosis and other nerve diseases
Disease control Recruiting nowThis early-phase trial is testing a new treatment called KITE-363 for people with certain autoimmune nerve diseases that have not responded to standard therapies. KITE-363 is a type of CAR T-cell therapy that uses a patient's own immune cells, modified to target and attack faulty…
Phase 1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Second chance: yescarta offered to lymphoma patients despite manufacturing hiccups
Disease control Expanded accessThis program offers Yescarta, a CAR T-cell therapy, to adults with large B-cell or follicular lymphoma whose manufactured batch didn't meet commercial standards but still meets clinical trial criteria. Participants receive a single infusion, and the goal is to provide access when…
Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Second chance: experimental access to CAR T-Cell therapy for patients whose treatment batches Don't meet commercial standards
Disease control Expanded accessThis expanded access study provides brexacabtagene autoleucel (Tecartus) to patients with mantle cell lymphoma or acute lymphoblastic leukemia whose commercially manufactured batch did not meet release specifications but still meets internal clinical trial criteria. Eligible pati…
Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC